Transform patients' lives withbest in class medicines
Advancing breakthrough treatments in oncology and immunology through cutting-edge research and development
Our Programs
A portfolio of 5 programs in immunology & oncology
Our Philosophy
Right team
Seasoned Drug Discovery and Development Team
Combine deep understanding of disease biology with >150 years of R&D experience and use of state-of-the-art technologies to de-risk early and accelerate value creation.
Right strategy
Patient Centric Strategy with focus on Clinically Validated Targets
Learn from the clinical liabilities of 1st generation drugs to design best-in-class medicines. Develop translational and mechanistic understanding to address liabilities and optimize drugs.
Right drugs
Best Therapeutic Modality For a Clinically Validated Target
Leverage both small and large molecule expertise to tailor drugs to the target biology. Design highly potent and selective drugs to limit off-target effects and optimize safety and efficacy.
Meet the Team
Pierre Raboisson
Chief Executive Officer
Marie De Vulder
Chief Legal Officer
François Gonzalvez
Chief Scientific Officer
Pieter Peeters
Chief Technology & Operations Officer
Guy Peeters
Chief Financial Officer
Sandrine Vendeville
VP, Head of Medicinal Chemistry
Joost Kolkman
VP, Head of Biologics
John-Paul Gallivan
SVP, Head of Development
Fabrice Kolb
VP, Head of Immunology
Ready to Learn More?
Discover how our innovative research is shaping the future of therapeutic medicine.